AHA and ASHP Push FDA on White Bagging Policies Affecting Specialty Drug Distribution

The American Hospital Association (AHA) and American Society of Health-System Pharmacists (ASHP) filed a citizen petition with FDA on March 18, 2025, requesting the agency restrict insurer-mandated white bagging practices for specialty pharmaceuticals. The petition argues that payer-controlled specialty pharmacy distribution undermines hospital oversight of drug handling and cold chain integrity—a concern that extends directly to the wholesale drug distributors and third-party logistics providers managing these transfers.

Regulatory Context

White bagging refers to the practice where payers require patients to obtain specialty medications from payer-designated specialty pharmacies rather than hospital or clinic pharmacies. The medication is shipped directly to the provider's facility for administration. This differs from brown bagging, where patients personally transport medications obtained from external pharmacies.

The FDA does not currently regulate white bagging practices as a distinct distribution model. Drug distribution falls under the Drug Supply Chain Security Act (DSCSA), which establishes transaction documentation and verification requirements for wholesale distributors, but does not address payer-mandated routing of specialty drugs. State boards of pharmacy regulate dispensing practices, creating a patchwork of rules across jurisdictions. The AHA-ASHP petition asks FDA to establish federal standards governing when and how payers can mandate white bagging arrangements.

Key Details of the Petition

The petition requests three specific FDA actions:

1. Prohibit white bagging for drugs requiring special handling. This includes temperature-sensitive biologics, drugs with REMS requirements, and medications with narrow therapeutic indices. The petition cites oncology drugs, ophthalmologic injectables, and hemophilia therapies as examples where loss of provider control over storage and handling creates patient safety risks.

1. Require payer transparency on white bagging policies. Insurers would be required to disclose which medications are subject to white bagging mandates and which specialty pharmacies are approved for distribution. The petition argues that hospitals currently cannot verify whether payer-designated distributors maintain appropriate licensure and accreditation.

1. Mandate compliance with DSCSA transaction requirements. The petition alleges that some white bagging arrangements bypass standard wholesale distribution channels, resulting in gaps in product tracing and verification. FDA would be asked to clarify that white bagging specialty pharmacy shipments must include full DSCSA transaction documentation, regardless of whether the shipment originates from a specialty pharmacy or distributor.

The petition does not propose specific deadlines. AHA and ASHP request FDA review under 21 CFR 10.30, which requires the agency to respond within 180 days.

Impact on Wholesale Drug Distribution

For wholesale drug distributors and 3PLs handling specialty pharmaceuticals, the petition highlights existing friction in the specialty drug logistics chain:

Licensure verification gaps. Hospitals report difficulty confirming that payer-designated specialty pharmacies and their distribution partners hold active wholesale drug distributor licenses in the state where the hospital is located. Under current DSCSA enforcement, the hospital is the final dispenser and must verify authorized trading partners, but payers do not consistently provide distributor license information.

Cold chain custody transfers. White bagging introduces additional handoffs between the specialty pharmacy, the distributor or courier, and the hospital receiving dock. Each transfer point creates potential for temperature excursion. The petition argues that hospitals lack visibility into cold chain validation data when the shipment originates outside their contracted distributor network.

DSCSA transaction documentation. Some white bagging shipments arrive without complete transaction history. Hospitals report receiving specialty drugs with partial or missing T3 documentation, making ATP verification difficult. Distributors participating in white bagging arrangements must determine whether they are acting as wholesale distributors (subject to full DSCSA requirements) or as agents of the dispensing pharmacy (potentially exempt under state pharmacy law but creating federal compliance ambiguity).

Recall coordination. When a specialty drug subject to white bagging is recalled, hospitals may not have direct contractual relationships with the distributor who delivered the product. The petition notes delays in recall notification when the distributor considers the payer specialty pharmacy—not the hospital—as the customer of record.

The petition does not propose changes to NABP VAWD accreditation requirements or state licensure rules, but it implicitly questions whether existing oversight mechanisms adequately cover payer-driven distribution models that bypass traditional hospital specialty pharmacy channels.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs, of which 63 hold NABP VAWD accreditation—the voluntary third-party verification that hospitals typically use to confirm distributor compliance posture. This represents 4.9% of the tracked universe. For hospitals attempting to verify payer-designated specialty pharmacy distributors under white bagging arrangements, the limited NABP accreditation rate means most entities must be verified through manual license and FDA registration checks.

The average compliance score across all tracked entities is 51/100, placing the majority in the "Fair" tier. Only 28 entities (2.2%) score in the "Excellent" range (76-100 points), which typically requires active state licenses in 40+ jurisdictions, NABP accreditation, FDA registration, and no enforcement actions on record. The petition's concern about licensure verification gaps is reflected in this distribution: 919 entities fall into the "Fair" tier, meaning they meet basic requirements but lack the cross-referenced compliance signals that would confirm robust multi-state distribution capabilities.

Of the 1,234 entities with verified FDA registration, 73 have recalls on record. For specialty drugs subject to white bagging, this raises a specific operational question: when a hospital receives a shipment from a payer-designated distributor, does the hospital's intake process include checking whether that distributor has recent recall history? ColdChainCheck data suggests most entities in the directory have clean records, but the 5.7% recall rate is high enough that blind acceptance of white-bagged shipments without distributor verification creates measurable exposure.

Practical Guidance for QA and Compliance Teams

Verify distributor licenses before accepting white-bagged shipments. Use the ColdChainCheck directory to confirm that the payer-designated specialty pharmacy's distributor holds active wholesale drug licenses in your state. Filter by state jurisdiction and check the entity's compliance score breakdown to see licensure coverage.

Check for NABP VAWD accreditation. If the distributor lacks NABP accreditation, request proof of state licensure and FDA registration directly from the payer. VAWD-accredited entities are marked in the directory and represent a higher baseline of verified compliance. See the NABP VAWD accreditation guide for verification procedures.

Review recall history. Before establishing white bagging arrangements with a new payer-designated distributor, check whether the entity has FDA recalls or warning letters on record. ColdChainCheck surfaces this data in the entity profile under enforcement actions.

Document ATP verification. Under DSCSA, hospitals must verify authorized trading partners before accepting product. If the white bagging shipment does not include complete transaction documentation, require the payer to provide distributor license and FDA registration numbers. Cross-reference these against ColdChainCheck data to confirm the entity is trackable in public records.

For ongoing monitoring of specialty pharmacy distribution compliance developments, see ColdChainCheck's regulatory guides, which track state-level licensing changes and federal DSCSA enforcement updates.

Disclaimer: This article provides informational analysis of regulatory developments and is not legal or compliance advice. Verify all distributor credentials and compliance status with the relevant state board of pharmacy and FDA before establishing trading partner relationships.